由 jpichiban 欧姆龙计划扩大其家用心电记录仪的销售，目标在2024年将全球销量翻番至20万台。该公司已在中国获得医疗器械许可，并于5月开始通过药店等渠道销售。同时，欧姆龙将在欧洲加强面向医疗机构的营销，通过代理商提升产品知名度，并计划在2025年后扩大至英国和德国。欧姆龙认为，尽管智能手表等设备具备心电监测功能，但老年人等群体仍需专用设备。该公司希望通过扩大心电记录仪的销售，将医疗保健业务发展成为业绩的增长引擎，弥补工厂自动化设备业务受中国需求下降的影响。
Original Title: 欧姆龙将在中国和欧洲扩大销售心电记录仪
Summary: OMRON plans to expand sales of its home electrocardiogram (ECG) recorder, aiming to double global sales to 200,000 units in 2024. The company has obtained medical device approval in China and started selling through drugstores and other channels in May. At the same time, OMRON will strengthen marketing efforts towards medical institutions in Europe, increase product visibility through agents, and plans to expand to the UK and Germany after 2025. OMRON believes that although devices such as smartwatches have ECG monitoring capabilities, there is still a need for dedicated devices among older people and other groups. The company hopes to develop its healthcare business into a growth engine by expanding ECG recorder sales, mitigating the impact of declining demand in China for factory automation equipment.
Original article: http://cn.nikkei.com/industry/manufacturing/56516-2024-08-26-10-25-36.html?print=1